Brief: Grand Pharmaceutical Group Posts H1 Revenue Of HKD6,047.24 Mln
19/08/2024 14:36
Aug 19 (Reuters) - Grand Pharmaceutical Group H1 revenue HKD 6,047.24 million. * H1 net income attributable HKD 1,557.95 million
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement